LUND, Sweden & ROCKVILLE, Md.--(BUSINESS WIRE)--BioInvent International AB (STO:BINV) and Human Genome Sciences, Inc. (NASDAQ:HGSI) today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies which specifically target antigens discovered by HGS.
